ondasdechoque.org
PT-BR

Post-stroke spasticity and motor function · Randomized trial · 2026

Can shockwave help arm movement months after a stroke?

In this trial, arm movement scores rose from about 22 to about 27 out of 66, a month after four sessions of radial shockwave, one a week, while the sham group stayed near 14. Gains were clearest at the shoulder and elbow.

Possible early help for arm movement
adults 6–24 months after a first stroke
23
sessions, one a week
4
weeks from start to final check
8

Good to know: No one had other treatment during the study.

Imamura M, Sugawara AT, Santos ACA, et al. Clinics (Sao Paulo, Brazil), 2026 · Read the paper ↗

How this study worked

Radial shockwave12 peopleSham shockwave11 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

What happened

Arm movement after a stroke

Fugl–Meyer arm score, 0–66 · start and week 8

StartWeek 8

Scores rose from about 22 to 27 with shockwave and stayed near 14 with sham. The two groups started at different levels.
Show the numbers
GroupPeopleStartWeek 8
Radial shockwave922.3327.44
Sham shockwave714.1413.86

The treatment

Radial shockwave

Radial, once a week for 4 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
4, one a week
Pulses
5,000 per session · spread over the forearm and hand muscles
Strength
3.5–4.0bar about 0.07 mJ/mm²; set to what each person could tolerate · 15 per second
Numbing
Not mentioned
Device
Swiss Dolorclast

Compared with: Sham shockwave: a handpiece that looked and sounded the same but gave no pulses

Settings are what each study used, not a prescription.

Who took part

23 adults 6–24 months after a first stroke; none had a measurable brain-to-arm nerve signal at the start.

hollow squares: no final score

Radial shockwave9 of 12 measured
Sham shockwave7 of 11 measured
16 of 23 people (70%) had a final score.

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with first ischemic stroke in middle cerebral artery territory, 6–24 months prior, imaging-confirmed; all 23 recruited participants lacked detectable MEP at baseline.

Radial ESWT12randomized

The article reports 23 total randomized. Table 1 lists 12 active-arm and 11 sham-arm participants; final per-protocol comparison used 9 and 7, respectively.

Sham radial ESWT11randomized

The article reports 23 total randomized. Table 1 lists 12 active-arm and 11 sham-arm participants; final per-protocol comparison used 9 and 7, respectively.

Fugl-Meyer Upper Extremity total score (primary)1 reported outcome
01
Four weeks after the final session (8 weeks after baseline)

Fugl-Meyer Upper Extremity total score (primary)

FMA-UE global score

BaselineFollow-up
Radial ESWT
27.444
Sham radial ESWT
13.857
066 score
means
GroupnBaselineFollow-up
Radial ESWT922.33327.444
Sham radial ESWT714.14313.857

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

ANCOVA estimated marginal mean difference7.319Uncertainty interval unavailablep = 0.038

rESWT minus sham

1 study · 16 participants in this estimate

ANCOVA adjusted for baseline; per-protocol

REPORTED COMPARISON TESTp = 0.038

rESWT versus sham, per-protocol

ANCOVA; alternative tests: Student p=0.096, Welch p=0.091, Hotelling T² p=0.037, Johansen T² p=0.033

ANCOVA and the two T² methods favor rESWT, but Student/Welch comparisons of change were not significant. No adjusted CI.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Proximal FMA-UE score1 reported outcome
02
Four weeks after the final session (8 weeks after baseline)

Proximal FMA-UE score

FMA-UE proximal score

BaselineFollow-up
Radial ESWT
13
Sham radial ESWT
5.143
030 score
means
GroupnBaselineFollow-up
Radial ESWT910.44413
Sham radial ESWT76.2865.143

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

ANCOVA estimated marginal mean difference4.987Uncertainty interval unavailablep = 0.030

rESWT minus sham

1 study · 16 participants in this estimate

ANCOVA adjusted for baseline; per-protocol

REPORTED COMPARISON TESTp = 0.030

rESWT versus sham, per-protocol

ANCOVA; alternative tests: Student p=0.100, Welch p=0.106, Hotelling T² p=0.027, Johansen T² p=0.028

Adjusted and T² tests favor rESWT, while unadjusted change t tests are not significant. This is a decomposed outcome the authors say was proposed after recognizing proximal/distal responses may differ.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported. The abstract reports p=0.004, whereas Table 5 reports ANCOVA p=0.030 and T² p=0.027/0.028; unresolved reporting discrepancy.

Distal FMA-UE score1 reported outcome
03
Four weeks after the final session (8 weeks after baseline)

Distal FMA-UE score

FMA-UE distal score

BaselineFollow-up
Radial ESWT
8.667
Sham radial ESWT
2.714
024 score
means
GroupnBaselineFollow-up
Radial ESWT95.2228.667
Sham radial ESWT72.7142.714

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

ANCOVA estimated marginal mean difference4.313Uncertainty interval unavailablep = 0.095

rESWT minus sham

1 study · 16 participants in this estimate

ANCOVA adjusted for baseline; per-protocol

REPORTED COMPARISON TESTp = 0.095

rESWT versus sham, per-protocol

ANCOVA; alternative tests: Student p=0.161, Welch p=0.140, Hotelling T² p=0.168, Johansen T² p=0.134

No statistically significant between-group effect across reported tests.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Muscle strength (secondary, exploratory)1 reported outcome
04
Four weeks after the final session (8 weeks after baseline)

Muscle strength (secondary, exploratory)

MRC Scale score

means
GroupnBaselineFollow-up
Radial ESWT91.8022.37
Sham radial ESWT71.4131.206

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

ANCOVA estimated marginal mean difference0.888Uncertainty interval unavailablep = 0.012

rESWT minus sham

1 study · 16 participants in this estimate

ANCOVA adjusted for baseline; per-protocol

REPORTED COMPARISON TESTp = 0.012

rESWT versus sham, per-protocol

ANCOVA; alternative tests: Student p=0.030, Welch p=0.025, Hotelling T² p=0.030, Johansen T² p=0.021

Between-group tests favor rESWT; the authors call this secondary and exploratory. No adjusted CI or validated aggregate scale range is reported.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Flexor muscle spasticity1 reported outcome
05
Four weeks after the final session (8 weeks after baseline)

Flexor muscle spasticity

Modified Ashworth Scale, flexors score

means
GroupnBaselineFollow-up
Radial ESWT91.2590.833
Sham radial ESWT70.6670.762

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.584

rESWT versus sham, per-protocol

Johansen T²; authors identify it as the most reliable test after assumptions for other methods were violated; p=0.584

The author-preferred Johansen test found no between-group difference. Student/Welch and ANCOVA results differ, and univariate normality, bivariate homoscedasticity, dissociation and parallelism were rejected; do not infer benefit from a single test.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Extensor muscle spasticity1 reported outcome
06
Four weeks after the final session (8 weeks after baseline)

Extensor muscle spasticity

Modified Ashworth Scale, extensors score

means
GroupnBaselineFollow-up
Radial ESWT92.2592.148
Sham radial ESWT72.1432.19

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.618

rESWT versus sham, per-protocol

Reported comparative tests: Welch p=0.618, ANCOVA p=0.714, Hotelling T² p=0.908, Johansen T² p=0.903

Reported tests found no between-group difference.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Grip strength1 reported outcome
07
Four weeks after the final session (8 weeks after baseline)

Grip strength

Grip dynamometer kg-force

means
GroupnBaselineFollow-up
Radial ESWT95.6117.556
Sham radial ESWT62.5713

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.347

rESWT versus sham, per-protocol

Reported tests: Welch p=0.347, ANCOVA p=0.535, Hotelling T² p=0.960, Johansen T² p=0.946

No reliable between-group difference established; sham-group linearity test did not converge and assumptions were not fully met.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham, but Table 4 marks sham participant 19's post-treatment grip value as missing: the sham follow-up mean (3.000) and the between-group tests (Student t(13), ANCOVA t(12), T²(2,14)) use 6 sham participants, while the printed sham baseline mean (2.571) includes all 7. The printed sham difference 1.083 is therefore not 3.000 − 2.571 (0.429); it matches the mean change of the 6 sham participants with both values in Table 4. Values are kept as printed. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

Pinch strength1 reported outcome
08
Four weeks after the final session (8 weeks after baseline)

Pinch strength

Pinch dynamometer kg-force

means
GroupnBaselineFollow-up
Radial ESWT91.3222.05
Sham radial ESWT60.4570.583

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.160

rESWT versus sham, per-protocol

Reported tests: Welch p=0.160, ANCOVA p=0.139, Hotelling T² p=0.307, Johansen T² p=0.228

No reliable between-group difference established; repeated zero values and rejected normality make the findings inconclusive.

Analysis details and source

Per-protocol n=9 rESWT and n=7 sham, but Table 4 marks sham participant 19's post-treatment pinch value as missing: the sham follow-up mean (0.583) and the between-group tests (Student t(13), ANCOVA t(12), T²(2,14)) use 6 sham participants, while the printed sham baseline mean (0.457) includes all 7. The printed sham difference 0.217 is therefore not 0.583 − 0.457 (0.126); it matches the mean change of the 6 sham participants with both values in Table 4. Values are kept as printed. Primary and secondary inferential tests are method-dependent; no confidence interval for adjusted estimates is reported.

How treatment was delivered
Radial shockwave device and dose

Swiss Dolorclast; 36-mm applicator with Power+ handpiece; 5,000 continuous pulses per session at 15 Hz; 3.5–4.0 bar, approximately 0.07 mJ/mm²; pressure/energy individually adjusted to maximum tolerance; 4 weekly sessions.

Treatment targets

Diffuse treatment of elbow and wrist flexors in the forearm and hand interossei.

Sham comparator

Handpiece appeared, felt, and sounded the same but emitted no shockwave or tactile sensation; active/sham applied at four weekly visits.

Co-interventions

No other intervention was given during the study period.

HARMS & TOLERABILITY

No systematic arm-specific adverse-event counts are reported. Seven participants were not included in the final per-protocol analysis due to botulinum toxin, withdrawal, or missing follow-up; the article does not establish that these were all treatment-related events.

LIMITS OF THE ANALYSIS

Only 16/23 randomized were included in the final per-protocol analysis; the article does not provide an intention-to-treat effect estimate.

The primary statistical inference is method-dependent: t tests of change were not significant, while baseline-adjusted ANCOVA and T² approaches were significant for total/proximal FMA-UE. No confidence intervals are reported.

The per-protocol analysis, short post-treatment follow-up and restriction to absent-baseline-MEP patients limit generalizability.

Several secondary outcomes violate model assumptions; authors identify the Johansen T² test as most reliable for flexor MAS, which found no difference. Pinch results are inconclusive because of zeros and distribution/linearity issues.

The sham did not provide tactile sensation, creating a possible clue to allocation; the paper nevertheless describes patients as blinded.

The paper discloses an author’s consultancy relationship with the device manufacturer; authors state the manufacturer had no role in the trial.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Only 16/23 randomized were included in the final per-protocol analysis; the article does not provide an intention-to-treat effect estimate.
  • The primary statistical inference is method-dependent: t tests of change were not significant, while baseline-adjusted ANCOVA and T² approaches were significant for total/proximal FMA-UE. No confidence intervals are reported.
  • The per-protocol analysis, short post-treatment follow-up and restriction to absent-baseline-MEP patients limit generalizability.
  • Several secondary outcomes violate model assumptions; authors identify the Johansen T² test as most reliable for flexor MAS, which found no difference. Pinch results are inconclusive because of zeros and distribution/linearity issues.
  • The sham did not provide tactile sensation, creating a possible clue to allocation; the paper nevertheless describes patients as blinded.
  • The paper discloses an author’s consultancy relationship with the device manufacturer; authors state the manufacturer had no role in the trial.
Research review

Source-linked critical reading

Randomized sham-controlled trial; per-protocol primary analysis

Reading depthMaterial consulted
Technical source record

Full article XML read: Abstract plus all 27 sections, five tables, four figure captions and author/declaration sections. Figure image files are absent from the retrieved package; graphical figures were not visually inspected.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Randomized double-blind sham-controlled trial at a single rehabilitation center in São Paulo; 23 randomized, 16 analyzed per protocol (9 active, 7 sham). Planned sample was 10 per arm.

Population

Adults ≥18 years with imaging-confirmed middle cerebral artery stroke 6–24 months earlier. All 23 recruited patients had absent MEPs at baseline, an unexpected finding not required by eligibility criteria.

Intervention protocol

Swiss Dolorclast, 36-mm applicator on Power+ handpiece; 4 weekly sessions; 5,000 continuous shocks/session at 15 Hz, 3.5–4.0 bar, approximately 0.07 mJ/mm²; pressure/energy adjusted to individual tolerance. Applied diffusely to elbow/wrist flexors in forearm and hand interossei.

Comparator and blinding

The sham handpiece looked, felt and sounded like the active one but emitted no ESWT and provided no tactile sensation. Patients and assessors were described as blinded; the no-sensation difference could reveal allocation.

Outcomes and timing

Primary outcome: global, proximal and distal FMA-UE at 4 weeks after the final treatment (8 weeks from baseline). Secondary outcomes: MRC strength, MAS flexor/extensor tone, grip and pinch strength, plus TMS measures. No usable comparative results for ICI/ICF/CSP are reported in the tables.

Comparative findings

For global FMA-UE, ANCOVA (baseline adjusted) and Hotelling/Johansen T² tests were significant, but Student/Welch tests of change were not; no adjusted CI was reported. Proximal FMA-UE had method-dependent findings. The abstract reports p=0.004, while Table 5 reports ANCOVA p=0.030 and Hotelling/Johansen p=0.027/0.028; the discrepancy is unresolved. Distal FMA-UE tests were nonsignificant. MRC favored active treatment but was explicitly exploratory. MAS flexor showed no between-group difference in the authors’ preferred Johansen test; grip and pinch results were inconclusive due to assumption violations.

Harms and tolerability

The article does not provide systematic arm-specific adverse-event counts. Reasons for discontinuation included botulinum toxin use, withdrawal, or missed follow-up; these should not all be attributed to treatment harms.

Limitations and uncertainty

Per-protocol analysis, with 7/23 randomized not included in the final analysis, and final evaluation only 4 weeks after treatment. All participants lacked MEP at baseline, limiting generalizability. Multiple tests produce inconsistent inference; several secondary tests violate assumptions. The sham provided no sensation. The manufacturer’s consultant relationship is disclosed, though authors state the manufacturer had no study role. Figure pixels were unavailable for visual inspection.

Applicability

Findings concern a selected chronic stroke subgroup with absent MEPs at one Brazilian center. They do not establish durable benefit, benefit in patients with preserved MEPs, or general effectiveness for stroke rehabilitation.

What stronger research should do

Conduct a larger preregistered multicenter trial with intention-to-treat analysis, a credible sensory-matched sham, longer follow-up, prespecified primary/global and segmental outcomes, correction for multiplicity, transparent assumptions and confidence intervals, systematic harms, and stratification by baseline MEP status.

THE ORIGINAL SOURCE

Read the original article.

Radial extracorporeal shock wave therapy improves upper limb function in chronic stroke patients: a randomized sham-controlled trial.

Imamura M, Sugawara AT, Santos ACA, Siqueira JO, Silveira PSP, Schmitz C, Battistella LR. · Clinics (Sao Paulo, Brazil) · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →